# Capacities of NPDE, VPC and pvcVPC at detecting model misspecification: a simulation study of a pharmacokinetic model showed no apparent difference

Anaïs Glatard, Thomas Dumortier, Jean-Louis Steimer, Céline Sarr

Pharmacometrics Novartis Pharma AG, Basel, Switzerland



# Background

- VPC (Visual Predictive Check), pvcVPC (prediction- and variability-corrected VPC)<sup>1</sup>, and NPDE (Normalised-Prediction Distribution Errors)<sup>2</sup> are three simulation-based model evaluation methods
- VPC is a within-bin comparison of the empirical distribution of the observations with the
- NPDE are individual comparisons of each observation with the corresponding model-based prediction,
- pvcVPC and NPDE have the capacity to detect model misspecification in the additional context of covariate heterogeneity
- Unfortunately, there is no information in the literature comparing their performances

### Conclusion

In a situation with a non-linear model and heterogeneity coming from a covariate, pvcVPC did not completely remove the heterogeneity of the prediction distribution across covariate levels but

corresponding model-based predictions.

 pvcVPC is the same methodology as VPC except that the observations are previously "corrected".
 Correction consists in prediction and variability correction of the observed and simulated data.

#### Objectives

 To investigate the capacity of these different methods at detecting a misspecified model in the context of high non-linearity and covariate heterogeneity this did not prevent the detection of the model misspecification. The NPDE method could detect the same model misspecification.

## Methods

- To assess the extent by which the pvcVPC corrects for heterogeneity and how the prediction distribution would be homogeous after correction, the distribution of the prediction (defined by Y<sub>i</sub> = f(θ<sub>i</sub>) + ε<sub>i</sub> for an individual i at a specified time point with θ<sub>i</sub> the vector of the individual parameters and ε<sub>i</sub> the residual error) before and after correction were obtained after simulation of 1000 PK profiles for a range of covariate value (using R v. 2.15.2). The PK profiles were simulated by a model included high non-linearity because the correction would expectedly be difficult. This process has been done in two situations defined by two different experimental designs and a pair of a true and a wrong models (see Table 1).
- To investigate the capacity of these different methods at detecting a misspecified model (wrong model), NPDE, VPC and pvcVPC were generated after estimation of the true and the wrong model on a dataset simulated with the true model including 5 subjects per covariate and dose level (using NONMEM v.7.2 and PsN v.3.5.3).
   Table 1. Description the situations 1 and 2, the study design and features of the True/Wrong models (differences are highlighted in bold).

	Situation 1		Situation 2	
	True model	Wrong model	True model	Wrong model
Type of model	2 cp PK model	1 cp PK model	2 cp PK model	1 cp PK model
Absorption	Bolus, no KA	Bolus, no KA	First Order	First Order
Elimination	Linear			
Residual error model	Additive on a log scale			
Individual parameters including the covariate	V1 = TVV1 * (WT/70) * EXP(ETA(1)) V2 = TVV2 * ((WT/70)**3) * EXP(ETA(2)) CL = TVCL * ((WT/70)**0.75) * EXP(ETA(3))	V = TVV * ((WT/70)**3) * EXP(ETA(1)) CL = TVCL * ((WT/70)**0.75) * EXP(ETA(2))	KA = TVKA * COVA * EXP(ETA(4))	KA = TVKA * COVA * EXP(ETA(4))
Typical parameters values	TVV1 = 10 L ; TVV2 = 300 L ; TVQ = 10 L/h TVCL = 2 L/h Residual error: $W = 0.2$	TVV = 40 L ; TVCL = 3 L/h Residual error: W = $0.2$	TVV1 = 209 L ; <b>TVV2= 530 L ; TVQ = 53 L/h</b> <b>TVCL = 19 L/h ; TVKA = 0.001 h<sup>-1</sup></b> Residual error: W = 0.2	TVV = 209 L ; TVCL = 25 L/h ; TVKA = 0.0007 h <sup>-1</sup> Residual error: W = 0.2
Inter-individual variability (variance)	OMV1 = 0.5 ; OMV2 = 0.5 ; OMQ = 0.5 OMCL = 0.5	OMV = 0.5 ; OMCL = 0.5	OMV2 = 0.2 ; OMV3 = 0.2 ; OMCL = 0.2 OMKA = 0.5	OMV = 0.2 ; OMCL = 0.2 ; OMKA = 0.5
Covariate values	Weight in kg (WT) : 40, 60, 80, 100, 120		COVA : 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, 4096	
Dose	100 mg or 300 mg at t=0, one single dose		10 mg at t=0, one single dose	

#### Results

The results for the situation 1 and 2 were similar. Below the results for the situation 2 with the wrong model are presented. It was the worse situation where a priori
the correction will have the most difficulty to compensate heterogeneity.

Figure 1. Prediction distribution at t = 1h after 10 mg administration. Dashed lines represents percentiles: the 1st quartile in green, the median in red and the 3rd quartile in blue. (a) prediction  $(y_{ij})$  distribution are heterogeneous across the covariate values as it is expected for a large covariate range. (b) prediction  $(pvcy_{ij})$  distribution have same mean, same standard error but there is still some degrees of heterogeneity in shape.

#### (a) Before correction



#### (b) After correction

# (a) VPC (b) pvcVPC

Figure 2. The wrong model is rejected by (a) VPC, (b) pvcVPC and (c) NPDE



#### (c) NPDE





- Prediction distribution before correction in the two situations were very different depending on the covariate value.
- NPDE and pvcVPC take into account heterogeneity due to the covariate while VPC does not.
- Further investigation on how NPDE and pvcVPC could handle heterogeneity would include:
  - Unbalanced design in simulation scenarios with doses in mg/kg.
  - Impact assessment of data not collected at the same time but with different time point within windows around a time point.

**References:** 1. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-Corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS Journal, 2011, 13(2):143-151 2. Comets E, Brendel K, Mentre F. Computing normalized prediction distribution errors to evaluate nonlinear mixed-effects models : the npde add-on package for R. Computer Methods and Programs in Biomedecine, 2008, 90:154-166

This study was supported by The Drug Disease Model Resources (DDMoRe) consortium. Copyright © 2016 Novartis Pharma AG, Basel, Switzerland. All rights reserved.

Poster presented at the Population Approach Group Europe (PAGE), June 7-10, 2016, Lisbon, Portugal.

Acknowledgments: Mick Looby is acknowledged for his input to this work